Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01246908 · ClinicalTrials.gov registry record · Phase 2
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
A Phase 2 study, sponsored by CeNeRx BioPharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 360
- Enrollment target
NCT01246908: Completed Phase 2 study, sponsored by CeNeRx BioPharma.
NCT01246908 is a Phase 2 study that has completed, run by CeNeRx BioPharma. The registered enrollment target is 360 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (171% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01246908, a Phase 2 study, has completed, sponsored by CeNeRx BioPharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 360 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if CX157 is effective and safe in patients with treatment of treatment resistant depression over six weeks of treatment.
Primary Outcome
The MADRS will be administered by a trained rater at the study site and assess symptoms of depression.
Interventions
- DRUG Placebo
- DRUG CX157 (TriRima)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 360 participants |
| Start Date | 2010-11 |
| Est. Completion | 2012-05 |
| Phase | Phase 2 |
What the finished NCT01246908 record still lists
NCT01246908 is an interventional study that assigns participants to a tested intervention. The registered 360 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (171% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01246908 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01246908 about?
NCT01246908 is a clinical study titled "Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression". The purpose of this study is to determine if CX157 is effective and safe in patients with treatment of treatment resistant depression over six weeks of treatment.
What is the current status of trial NCT01246908?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 360 participants. The study started on 2010-11. Estimated completion is 2012-05.
What interventions are being tested in trial NCT01246908?
The interventions under investigation include: Placebo (DRUG), CX157 (TriRima) (DRUG).
Who is sponsoring clinical trial NCT01246908?
This trial is sponsored by CeNeRx BioPharma, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01246908's enrollment target sits among peer trials
360 123rd of 2000 higher than 1,874 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02747836 · 360 participants
Ultrasound Analysis of Human Carpal Tunnel System
- NCT04089046 · 360 participants · NA
Telemedicine Enhanced Asthma Management - Uniting Providers for Teens (TEAM-UP for Teens)
- NCT04130503 · 360 participants · NA
The Recovery in Stroke Using PAP Study
- NCT04160000 · 360 participants · Phase 4
Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia